Literature DB >> 31823071

Pharmacometabonomics: The Prediction of Drug Effects Using Metabolic Profiling.

Jeremy R Everett1.   

Abstract

Metabonomics, also known as metabolomics, is concerned with the study of metabolite profiles in humans, animals, plants and other systems in order to assess their health or other status and their responses to experimental interventions. Metabonomics is thus widely used in disease diagnosis and in understanding responses to therapies such as drug administration. Pharmacometabonomics, also known as pharmacometabolomics, is a related methodology but with a prognostic as opposed to diagnostic thrust. Pharmacometabonomics aims to predict drug effects including efficacy, safety, metabolism and pharmacokinetics, prior to drug administration, via an analysis of pre-dose metabolite profiles. This article will review the development of pharmacometabonomics as a new field of science that has much promise in helping to deliver more effective personalised medicine, a major goal of twenty-first century healthcare.

Entities:  

Keywords:  Metabolic phenotyping; Metabolomics; Metabonomics; Metabotypes; NMR spectroscopy; Personalised medicine; Pharmacometabolomics; Pharmacometabonomics; Precision medicine; Systems medicine

Year:  2019        PMID: 31823071     DOI: 10.1007/164_2019_316

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  3 in total

Review 1.  Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy.

Authors:  Do Hyeon Kwon; Ji Su Hwang; Seok Gi Kim; Yong Eun Jang; Tae Hwan Shin; Gwang Lee
Journal:  Int J Mol Sci       Date:  2022-02-07       Impact factor: 5.923

2.  The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC-IM-MS Study.

Authors:  Billy Molloy; Lauren Mullin; Adam King; Lee A Gethings; Robert S Plumb; Ian D Wilson
Journal:  Metabolites       Date:  2021-06-11

3.  Self-Reported Medication Use and Urinary Drug Metabolites in the German Chronic Kidney Disease (GCKD) Study.

Authors:  Fruzsina Kotsis; Ulla T Schultheiss; Matthias Wuttke; Pascal Schlosser; Johanna Mielke; Michael S Becker; Peter J Oefner; Edward D Karoly; Robert P Mohney; Kai-Uwe Eckardt; Peggy Sekula; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2021-06-17       Impact factor: 14.978

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.